Don't Overlook AptarGroup (ATR) International Revenue Trends While Assessing the Stock
Explore how AptarGroup's (ATR) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
AptarGroup, Inc. (ATR) Q4 2025 Earnings Call Transcript
AptarGroup, Inc. (ATR) Q4 2025 Earnings Call Transcript
AptarGroup (ATR) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for AptarGroup (ATR) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
AptarGroup (ATR) Q4 Earnings and Revenues Surpass Estimates
AptarGroup (ATR) came out with quarterly earnings of $1.25 per share, beating the Zacks Consensus Estimate of $1.24 per share. This compares to earnings of $1.52 per share a year ago.
Earnings Preview: AptarGroup (ATR) Q4 Earnings Expected to Decline
AptarGroup (ATR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in AptarGroup Stock?
Investors need to pay close attention to ATR stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in AptarGroup Stock?
Investors need to pay close attention to ATR stock based on the movements in the options market lately.
AptarGroup, Inc. (ATR) Presents at Jefferies London Healthcare Conference 2025 Transcript
AptarGroup, Inc. ( ATR ) Jefferies London Healthcare Conference 2025 November 19, 2025 7:00 AM EST Company Participants Stephan Tanda - President, CEO & Executive Director Gael Touya - President of Aptar Pharma Vanessa Kanu - Executive VP & CFO Conference Call Participants Daniel Rizzo - Jefferies LLC, Research Division Presentation Daniel Rizzo Jefferies LLC, Research Division Good afternoon. I am Dan Rizzo with Jefferies Equity Research.
AptarGroup: Pharma Setback Creates Long-Term Opportunities
AptarGroup's shares have dropped over 25% from summer highs due to slower growth, especially in high-margin pharma emergency solutions. ATR's valuation has compressed from 26x to 20x earnings, reflecting concerns about flat growth and a soft outlook for 2026. Pharma remains the most profitable segment, but headwinds in emergency-use delivery systems are expected to impact revenues next year.
Compared to Estimates, AptarGroup (ATR) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for AptarGroup (ATR) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
AptarGroup (ATR) Q3 Earnings and Revenues Top Estimates
AptarGroup (ATR) came out with quarterly earnings of $1.62 per share, beating the Zacks Consensus Estimate of $1.57 per share. This compares to earnings of $1.49 per share a year ago.
3 Industrial Stocks Set to Outshine Q3 Earnings Estimates
Three industrial stocks-AptarGroup, Tennant and Sealed Air-look poised to beat Q3 earnings, driven by strong end-market demand and pricing gains.
